Intrinsic value of Glaukos - GKOS

Previous Close

$37.45

  Intrinsic Value

$493.88

stock screener

  Rating & Target

str. buy

+999%

  Value-price divergence*

+26%

Previous close

$37.45

 
Intrinsic value

$493.88

 
Up/down potential

+999%

 
Rating

str. buy

 
Value-price divergence*

+26%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of GKOS stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  58.33
  56.50
  51.35
  46.72
  42.54
  38.79
  35.41
  32.37
  29.63
  27.17
  24.95
  22.96
  21.16
  19.55
  18.09
  16.78
  15.60
  14.54
  13.59
  12.73
  11.96
  11.26
  10.64
  10.07
  9.56
  9.11
  8.70
  8.33
  7.99
  7.70
  7.43
Revenue, $m
  114
  178
  270
  396
  565
  784
  1,061
  1,405
  1,821
  2,316
  2,894
  3,558
  4,311
  5,154
  6,086
  7,107
  8,216
  9,411
  10,690
  12,051
  13,491
  15,011
  16,607
  18,280
  20,028
  21,852
  23,753
  25,731
  27,788
  29,926
  32,148
Variable operating expenses, $m
 
  53
  80
  118
  168
  234
  316
  419
  543
  690
  862
  1,060
  1,285
  1,536
  1,814
  2,118
  2,448
  2,804
  3,186
  3,591
  4,020
  4,473
  4,949
  5,447
  5,968
  6,512
  7,078
  7,668
  8,281
  8,918
  9,580
Fixed operating expenses, $m
 
  90
  92
  95
  97
  100
  102
  105
  107
  110
  113
  115
  118
  121
  124
  127
  131
  134
  137
  141
  144
  148
  151
  155
  159
  163
  167
  171
  176
  180
  185
Total operating expenses, $m
  110
  143
  172
  213
  265
  334
  418
  524
  650
  800
  975
  1,175
  1,403
  1,657
  1,938
  2,245
  2,579
  2,938
  3,323
  3,732
  4,164
  4,621
  5,100
  5,602
  6,127
  6,675
  7,245
  7,839
  8,457
  9,098
  9,765
Operating income, $m
  4
  35
  97
  183
  299
  451
  643
  882
  1,171
  1,516
  1,919
  2,382
  2,908
  3,496
  4,148
  4,862
  5,637
  6,473
  7,367
  8,319
  9,327
  10,390
  11,507
  12,677
  13,901
  15,177
  16,507
  17,892
  19,331
  20,828
  22,384
EBITDA, $m
  9
  37
  100
  188
  306
  460
  655
  898
  1,193
  1,543
  1,953
  2,424
  2,959
  3,557
  4,220
  4,946
  5,734
  6,584
  7,493
  8,461
  9,486
  10,567
  11,703
  12,893
  14,137
  15,435
  16,788
  18,195
  19,659
  21,181
  22,763
Interest expense (income), $m
  0
  0
  0
  1
  1
  2
  3
  5
  7
  9
  11
  14
  18
  22
  26
  31
  36
  42
  48
  55
  62
  70
  78
  86
  95
  104
  113
  123
  134
  144
  155
Earnings before tax, $m
  5
  35
  97
  183
  298
  448
  639
  877
  1,164
  1,507
  1,907
  2,368
  2,890
  3,475
  4,122
  4,831
  5,601
  6,430
  7,318
  8,264
  9,265
  10,320
  11,429
  12,591
  13,806
  15,073
  16,394
  17,768
  19,198
  20,684
  22,228
Tax expense, $m
  0
  9
  26
  49
  80
  121
  173
  237
  314
  407
  515
  639
  780
  938
  1,113
  1,304
  1,512
  1,736
  1,976
  2,231
  2,501
  2,786
  3,086
  3,400
  3,728
  4,070
  4,426
  4,797
  5,183
  5,585
  6,002
Net income, $m
  5
  26
  71
  133
  217
  327
  467
  640
  850
  1,100
  1,392
  1,728
  2,110
  2,536
  3,009
  3,526
  4,088
  4,694
  5,343
  6,032
  6,763
  7,534
  8,343
  9,191
  10,078
  11,004
  11,968
  12,971
  14,014
  15,099
  16,227

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  96
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  134
  59
  90
  132
  188
  261
  354
  468
  607
  772
  965
  1,186
  1,437
  1,718
  2,029
  2,369
  2,739
  3,137
  3,563
  4,017
  4,497
  5,004
  5,536
  6,093
  6,676
  7,284
  7,918
  8,577
  9,263
  9,975
  10,716
Adjusted assets (=assets-cash), $m
  38
  59
  90
  132
  188
  261
  354
  468
  607
  772
  965
  1,186
  1,437
  1,718
  2,029
  2,369
  2,739
  3,137
  3,563
  4,017
  4,497
  5,004
  5,536
  6,093
  6,676
  7,284
  7,918
  8,577
  9,263
  9,975
  10,716
Revenue / Adjusted assets
  3.000
  3.017
  3.000
  3.000
  3.005
  3.004
  2.997
  3.002
  3.000
  3.000
  2.999
  3.000
  3.000
  3.000
  3.000
  3.000
  3.000
  3.000
  3.000
  3.000
  3.000
  3.000
  3.000
  3.000
  3.000
  3.000
  3.000
  3.000
  3.000
  3.000
  3.000
Average production assets, $m
  14
  21
  32
  47
  67
  92
  125
  166
  215
  273
  341
  420
  509
  608
  718
  839
  969
  1,110
  1,261
  1,422
  1,592
  1,771
  1,960
  2,157
  2,363
  2,579
  2,803
  3,036
  3,279
  3,531
  3,794
Working capital, $m
  103
  11
  16
  24
  34
  48
  65
  86
  111
  141
  177
  217
  263
  314
  371
  434
  501
  574
  652
  735
  823
  916
  1,013
  1,115
  1,222
  1,333
  1,449
  1,570
  1,695
  1,826
  1,961
Total debt, $m
  0
  10
  23
  42
  67
  100
  141
  192
  254
  328
  414
  513
  625
  751
  890
  1,042
  1,207
  1,385
  1,576
  1,779
  1,993
  2,220
  2,457
  2,707
  2,967
  3,239
  3,522
  3,817
  4,123
  4,442
  4,773
Total liabilities, $m
  17
  27
  40
  59
  84
  117
  158
  209
  271
  345
  431
  530
  642
  768
  907
  1,059
  1,224
  1,402
  1,593
  1,796
  2,010
  2,237
  2,474
  2,724
  2,984
  3,256
  3,539
  3,834
  4,140
  4,459
  4,790
Total equity, $m
  117
  33
  50
  73
  104
  144
  196
  259
  336
  427
  533
  656
  795
  950
  1,122
  1,310
  1,514
  1,735
  1,970
  2,221
  2,487
  2,767
  3,061
  3,370
  3,692
  4,028
  4,378
  4,743
  5,122
  5,516
  5,926
Total liabilities and equity, $m
  134
  60
  90
  132
  188
  261
  354
  468
  607
  772
  964
  1,186
  1,437
  1,718
  2,029
  2,369
  2,738
  3,137
  3,563
  4,017
  4,497
  5,004
  5,535
  6,094
  6,676
  7,284
  7,917
  8,577
  9,262
  9,975
  10,716
Debt-to-equity ratio
  0.000
  0.290
  0.470
  0.580
  0.650
  0.690
  0.720
  0.740
  0.760
  0.770
  0.780
  0.780
  0.790
  0.790
  0.790
  0.800
  0.800
  0.800
  0.800
  0.800
  0.800
  0.800
  0.800
  0.800
  0.800
  0.800
  0.800
  0.800
  0.800
  0.810
  0.810
Adjusted equity ratio
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553
  0.553

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  5
  26
  71
  133
  217
  327
  467
  640
  850
  1,100
  1,392
  1,728
  2,110
  2,536
  3,009
  3,526
  4,088
  4,694
  5,343
  6,032
  6,763
  7,534
  8,343
  9,191
  10,078
  11,004
  11,968
  12,971
  14,014
  15,099
  16,227
Depreciation, amort., depletion, $m
  5
  2
  3
  5
  7
  9
  13
  17
  21
  27
  34
  42
  51
  61
  72
  84
  97
  111
  126
  142
  159
  177
  196
  216
  236
  258
  280
  304
  328
  353
  379
Funds from operations, $m
  6
  28
  74
  138
  224
  336
  479
  657
  872
  1,127
  1,426
  1,770
  2,161
  2,597
  3,081
  3,610
  4,185
  4,805
  5,469
  6,175
  6,922
  7,711
  8,539
  9,407
  10,315
  11,261
  12,248
  13,275
  14,342
  15,452
  16,606
Change in working capital, $m
  -6
  4
  6
  8
  10
  13
  17
  21
  25
  30
  35
  41
  46
  51
  57
  62
  68
  73
  78
  83
  88
  93
  97
  102
  107
  111
  116
  121
  125
  130
  136
Cash from operations, $m
  12
  24
  68
  130
  214
  323
  462
  636
  846
  1,097
  1,391
  1,730
  2,115
  2,546
  3,024
  3,548
  4,118
  4,732
  5,391
  6,092
  6,834
  7,618
  8,442
  9,305
  10,208
  11,150
  12,132
  13,154
  14,217
  15,322
  16,470
Maintenance CAPEX, $m
  0
  -1
  -2
  -3
  -5
  -7
  -9
  -13
  -17
  -21
  -27
  -34
  -42
  -51
  -61
  -72
  -84
  -97
  -111
  -126
  -142
  -159
  -177
  -196
  -216
  -236
  -258
  -280
  -304
  -328
  -353
New CAPEX, $m
  -6
  -8
  -11
  -15
  -20
  -26
  -33
  -41
  -49
  -58
  -68
  -78
  -89
  -99
  -110
  -121
  -131
  -141
  -151
  -161
  -170
  -179
  -188
  -197
  -206
  -215
  -224
  -233
  -243
  -252
  -262
Cash from investing activities, $m
  -26
  -9
  -13
  -18
  -25
  -33
  -42
  -54
  -66
  -79
  -95
  -112
  -131
  -150
  -171
  -193
  -215
  -238
  -262
  -287
  -312
  -338
  -365
  -393
  -422
  -451
  -482
  -513
  -547
  -580
  -615
Free cash flow, $m
  -14
  15
  55
  112
  189
  291
  420
  583
  780
  1,017
  1,296
  1,617
  1,984
  2,396
  2,853
  3,356
  3,903
  4,494
  5,129
  5,805
  6,522
  7,280
  8,076
  8,912
  9,786
  10,699
  11,650
  12,640
  13,670
  14,742
  15,855
Issuance/(repayment) of debt, $m
  -10
  10
  14
  19
  25
  33
  41
  51
  62
  74
  86
  99
  112
  126
  139
  152
  165
  178
  191
  203
  215
  226
  238
  249
  261
  272
  283
  295
  307
  319
  331
Issuance/(repurchase) of shares, $m
  8
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -2
  10
  14
  19
  25
  33
  41
  51
  62
  74
  86
  99
  112
  126
  139
  152
  165
  178
  191
  203
  215
  226
  238
  249
  261
  272
  283
  295
  307
  319
  331
Total cash flow (excl. dividends), $m
  -15
  24
  69
  131
  214
  323
  462
  634
  842
  1,091
  1,382
  1,716
  2,096
  2,521
  2,992
  3,508
  4,068
  4,672
  5,319
  6,008
  6,737
  7,506
  8,314
  9,161
  10,046
  10,970
  11,933
  12,935
  13,977
  15,060
  16,186
Retained Cash Flow (-), $m
  -22
  -12
  -17
  -23
  -31
  -40
  -51
  -63
  -77
  -91
  -107
  -122
  -139
  -155
  -172
  -188
  -204
  -220
  -236
  -251
  -266
  -280
  -294
  -308
  -322
  -336
  -350
  -365
  -379
  -394
  -410
Prev. year cash balance distribution, $m
 
  96
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  109
  52
  108
  183
  283
  411
  570
  766
  1,000
  1,275
  1,594
  1,957
  2,366
  2,820
  3,319
  3,864
  4,452
  5,083
  5,757
  6,471
  7,226
  8,020
  8,853
  9,724
  10,634
  11,583
  12,570
  13,598
  14,666
  15,776
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  104
  48
  94
  151
  219
  298
  385
  479
  574
  669
  757
  835
  900
  947
  975
  982
  969
  936
  886
  822
  747
  665
  580
  495
  414
  338
  270
  210
  160
  119
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Glaukos Corporation, an ophthalmic medical technology company, develops and commercializes products and procedures designed for the treatment of glaucoma. The company offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline comprises iStent Inject trabecular micro-bypass stent, which allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry with the goal of achieving intraocular pressure reduction; iStent Supra suprachoroidal micro-bypass stent that is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. The company markets its products through direct sales force in the United States, Germany, Australia, and Canada, as well as through distribution partners in Europe, the Asia Pacific, and internationally. Glaukos Corporation was founded in 1998 and is headquartered in Laguna Hills, California.

FINANCIAL RATIOS  of  Glaukos (GKOS)

Valuation Ratios
P/E Ratio 254.2
Price to Sales 11.1
Price to Book 10.9
Price to Tangible Book
Price to Cash Flow 105.9
Price to Free Cash Flow 211.8
Growth Rates
Sales Growth Rate 58.3%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -62.5%
Cap. Spend. - 3 Yr. Gr. Rate 43.1%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 4%
Ret/ On Assets - 3 Yr. Avg. -28.3%
Return On Total Capital 4.5%
Ret/ On T. Cap. - 3 Yr. Avg. -31.3%
Return On Equity 4.7%
Return On Equity - 3 Yr. Avg. -60.9%
Asset Turnover 0.9
Profitability Ratios
Gross Margin 86%
Gross Margin - 3 Yr. Avg. 80.6%
EBITDA Margin 8.8%
EBITDA Margin - 3 Yr. Avg. -18.9%
Operating Margin 3.5%
Oper. Margin - 3 Yr. Avg. -24.9%
Pre-Tax Margin 4.4%
Pre-Tax Margin - 3 Yr. Avg. -26.3%
Net Profit Margin 4.4%
Net Profit Margin - 3 Yr. Avg. -24.4%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

GKOS stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the GKOS stock intrinsic value calculation we used $114 million for the last fiscal year's total revenue generated by Glaukos. The default revenue input number comes from 2016 income statement of Glaukos. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our GKOS stock valuation model: a) initial revenue growth rate of 56.5% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for GKOS is calculated based on our internal credit rating of Glaukos, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Glaukos.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of GKOS stock the variable cost ratio is equal to 29.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $88 million in the base year in the intrinsic value calculation for GKOS stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Glaukos.

Corporate tax rate of 27% is the nominal tax rate for Glaukos. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the GKOS stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for GKOS are equal to 11.8%.

Life of production assets of 10 years is the average useful life of capital assets used in Glaukos operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for GKOS is equal to 6.1%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $117 million for Glaukos - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 32.977 million for Glaukos is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Glaukos at the current share price and the inputted number of shares is $1.2 billion.

RELATED COMPANIES Price Int.Val. Rating
STAA Staar Surgical 11.75 0.23  str.sell
IRIX Iridex 8.37 2.06  str.sell
EYES Second Sight M 0.970 0.06  str.sell
ABT Abbott Laborat 48.74 423.88  str.buy
NVS Novartis ADR 82.76 35.73  str.sell
RTIX RTI Surgical 4.65 1.53  str.sell

COMPANY NEWS

▶ Glaukos reports 2Q loss   [Aug-04-17 03:17AM  Associated Press]
▶ Here's What's Pressuring Glaukos Corp Stock Today   [Aug-03-17 01:17PM  Motley Fool]
▶ Glaukos Corp. Value Analysis (NYSE:GKOS) : August 1, 2017   [Aug-01-17 06:27PM  Capital Cube]
▶ ETFs with exposure to Glaukos Corp. : July 24, 2017   [Jul-24-17 04:08PM  Capital Cube]
▶ ETFs with exposure to Glaukos Corp. : July 11, 2017   [Jul-11-17 02:34PM  Capital Cube]
▶ ETFs with exposure to Glaukos Corp. : June 30, 2017   [Jun-30-17 02:57PM  Capital Cube]
▶ ETFs with exposure to Glaukos Corp. : June 19, 2017   [Jun-19-17 03:24PM  Capital Cube]
▶ 3 Growth Stocks for Bold Investors   [Jun-10-17 02:06PM  Motley Fool]
▶ Which Stocks Are Showing Rising Relative Strength?   [May-24-17 12:05PM  Investor's Business Daily]
▶ Can This 2015 Medical IPO Inject New Life Into Its Stock?   [12:03PM  Investor's Business Daily]
▶ Glaukos beats Street 1Q forecasts   [May-03-17 07:27PM  Associated Press]
▶ Glaukos Corp. Value Analysis (NYSE:GKOS) : May 1, 2017   [May-01-17 04:59PM  Capital Cube]
▶ 3 Stocks That Are Overvalued   [Apr-10-17 10:20AM  Motley Fool]
▶ [$$] Skeptics Eye Potential Trouble for Glaukos   [Apr-08-17 12:21AM  Barrons.com]
▶ ETFs with exposure to Glaukos Corp. : April 5, 2017   [Apr-05-17 04:49PM  Capital Cube]
▶ ETFs with exposure to Glaukos Corp. : March 6, 2017   [Mar-06-17 01:42PM  Capital Cube]
▶ 3 Most Wildly Overvalued Stocks in Healthcare   [09:24AM  at Motley Fool]
Stock chart of GKOS Financial statements of GKOS
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.